SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics PLC has announced the strategic acquisition of Bio-Tech Solutions Ltd for £1.25m, marking its second purchase in a merger and acquisition strategy designed to bolster manufacturing and packaging capabilities for health, hygiene, and personal care products. The cash and debt-free acquisition is expected to contribute to the Group’s revenue and EBITDA, as well as offering a future development platform for topical products, securing SkinBioTherapeutics’ operational cash runway until Summer 2026. The acquisition, funded through a combination of loan, equity, and cash reserves, aims to integrate BTS’s existing profitable business model with SkinBioTherapeutics’ portfolio to drive future growth and profitability.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
